(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 34.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.59%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.82%.
Tarsus Pharmaceuticals's revenue in 2026 is $451,360,000.On average, 11 Wall Street analysts forecast TARS's revenue for 2026 to be $30,072,400,572, with the lowest TARS revenue forecast at $28,430,532,531, and the highest TARS revenue forecast at $32,164,526,879. On average, 9 Wall Street analysts forecast TARS's revenue for 2027 to be $39,076,714,729, with the lowest TARS revenue forecast at $35,450,390,836, and the highest TARS revenue forecast at $44,174,676,696.
In 2028, TARS is forecast to generate $46,387,666,280 in revenue, with the lowest revenue forecast at $39,897,223,175 and the highest revenue forecast at $56,644,021,852.